Pawel Krawczyk
Overview
Explore the profile of Pawel Krawczyk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
179
Citations
1045
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nicos M, Sroka-Bartnicka A, Kalinka E, Krawczyk P
Cancers (Basel)
. 2025 Feb;
17(4).
PMID: 40002158
The advancement of genetic research has changed the treatment management of non-small cell lung cancer (NSCLC) and opened the era of personalized medicine. Currently, three generations of EGFR tyrosine kinase...
2.
Grenda A, Iwan E, Kuznar-Kaminska B, Bomba A, Bielinska K, Krawczyk P, et al.
Sci Rep
. 2025 Feb;
15(1):6139.
PMID: 39979394
The composition of the gut microbiome of patients with advanced non-small cell lung cancer is currently considered a factor influencing the effectiveness of treatment with immune checkpoint inhibitors. We aimed...
3.
Knetki-Wroblewska M, Wojas-Krawczyk K, Krawczyk P, Krzakowski M
Transl Lung Cancer Res
. 2025 Jan;
13(12):3718-3730.
PMID: 39830769
Immune checkpoint inhibitors (ICIs) have become an established treatment option for patients with advanced non-small cell lung cancer (NSCLC). However, the efficacy of single-agent immunotherapy as well as in combination...
4.
Krawczyk P, Klopotowska D, Matuszyk J
Biochem Biophys Rep
. 2024 Nov;
40:101853.
PMID: 39508056
TrkB and TrkC are quite common neurotrophin receptors found on the same cells in CNS. In the C-terminal tail, TrkB and TrkC differ only in two amino acid residues at...
5.
Chmielewska I, Krawczyk P, Wojcik-Superczynska M, Grenda A, Gil M, Stencel K, et al.
Transl Lung Cancer Res
. 2024 Nov;
13(10):2491-2499.
PMID: 39507034
Background: The use of immunotherapy in treatment of non-small cell lung cancer (NSCLC) patients with the gene mutations is an area of active research and is an item of clinical...
6.
Krawczyk P, Labinski J, Szczerba M, Smolinski M, Sienko M
J Sports Med Phys Fitness
. 2024 Sep;
64(12):1267-1277.
PMID: 39264223
Background: The study aimed to try to determine whether there are differences in performance analysis in handball matches won and lost, in Pre-COVID-19, COVID-19, and Post-COVID-19 seasons, taking into account...
7.
Wojas-Krawczyk K, Krawczyk P, Blach J, Kucharczyk T, Grenda A, Krzyzanowska N, et al.
BMC Infect Dis
. 2024 Aug;
24(1):865.
PMID: 39187767
Background: The immunological background responsible for the severe course of COVID-19 and the immune factors that protect against SARS-CoV-2 infection are still unclear. The aim of this study was to...
8.
Iwan E, Grenda A, Bomba A, Bielinska K, Wasyl D, Kieszko R, et al.
Front Genet
. 2024 Aug;
15:1378900.
PMID: 39170692
Background: The newest method of treatment for patients with NSCLC (non-small cell lung cancer) is immunotherapy directed at the immune checkpoints PD-1 (Programmed Cell Death 1) and PD-L1 (Programmed Cell...
9.
Gawel K, Hulas-Stasiak M, Marszalek-Grabska M, Grenda A, Siekierska A, Kosheva N, et al.
Front Mol Neurosci
. 2024 Aug;
17:1418606.
PMID: 39165716
Objective: Preclinical models of seizures and epilepsy in rodents contributed substantially to the discovery of currently available antiseizure medications. These were also broadly used for investigation of processes of epileptogenesis....
10.
Frak M, Grenda A, Krawczyk P, Kuznar-Kaminska B, Pazdrowski P, Kedra K, et al.
BMC Cancer
. 2024 Aug;
24(1):937.
PMID: 39090596
Introduction: Neuropeptide Y is a neurotransmitter in the nervous system and belongs to the orexigenic system that increases appetite. Its excessive secretion leads to obesity. Leptin is a pro-inflammatory adipokine...